NCT00794001 Feedback Intervention and Treatment Times in ST- Elevation Myocardial Infarction
| NCT ID | NCT00794001 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Karl Heinrich Scholz |
| Condition | Myocardial Infarction |
| Study Type | INTERVENTIONAL |
| Enrollment | 50,000 participants |
| Start Date | 2007-10 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50,000 participants in total. It began in 2007-10 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Part I (Pilot Phase): The purpose of this study is to examine if formalized data assessment and systematic feedback improves treatment times (i.e. contact-to-balloon time and door-to-balloon time) in patients with myocardial infarction with ST-segment elevation (STEMI). Part II (Implementation Phase): The Purpose is to prospectively investigate if survival can be improved by stringent use of this concept of formalized data analysis and systematic feedback of procedural and clinical data to all participating physicians and other members of the STEMI patients treating personnel. Part III (Advance Phase): The purpose is to develop, introduce and evaluate prospectively an automated, highly standardized feedback tool informing participating centers on key performance characteristics (procedural and clinical outcomes).
Eligibility Criteria
Inclusion Criteria: * all patients who received a diagnosis of STEMI\* and were transported to the cardiac catheterization laboratory of the primary PCI center with the intention to perform primary PCI. * STEMI definition: * elevation of the ST-segments of greater than or equal to 0.1 mV in at least two contiguous limb- or precordial leads * new or presumable new left bundle branch block in the presence of typical symptoms Exclusion Criteria: * STEMI-patients with duration of infarct-related symptoms longer than 24 hours are excluded
Contact & Investigator
Karl H. Scholz, MD.
STUDY DIRECTOR
St.Bernward Hospital
Frequently Asked Questions
Who can join the NCT00794001 clinical trial?
This trial is open to participants of all sexes, studying Myocardial Infarction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00794001 currently recruiting?
Yes, NCT00794001 is actively recruiting participants. Contact the research team at k.scholz@fitt-stemi.de for enrollment information.
Where is the NCT00794001 trial being conducted?
This trial is being conducted at Hildesheim, Germany.
Who is sponsoring the NCT00794001 clinical trial?
NCT00794001 is sponsored by Karl Heinrich Scholz. The principal investigator is Karl H. Scholz, MD. at St.Bernward Hospital. The trial plans to enroll 50,000 participants.